KR102213514B1 - Natural composition for inhibiting corona virus activity - Google Patents

Natural composition for inhibiting corona virus activity Download PDF

Info

Publication number
KR102213514B1
KR102213514B1 KR1020200090797A KR20200090797A KR102213514B1 KR 102213514 B1 KR102213514 B1 KR 102213514B1 KR 1020200090797 A KR1020200090797 A KR 1020200090797A KR 20200090797 A KR20200090797 A KR 20200090797A KR 102213514 B1 KR102213514 B1 KR 102213514B1
Authority
KR
South Korea
Prior art keywords
weight
parts
composition
antiviral
virus
Prior art date
Application number
KR1020200090797A
Other languages
Korean (ko)
Inventor
김성재
Original Assignee
김성재
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김성재 filed Critical 김성재
Priority to KR1020200090797A priority Critical patent/KR102213514B1/en
Application granted granted Critical
Publication of KR102213514B1 publication Critical patent/KR102213514B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13Coniferophyta (gymnosperms)
    • A61K36/14Cupressaceae (Cypress family), e.g. juniper or cypress
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/32Burseraceae (Frankincense family)
    • A61K36/324Boswellia, e.g. frankincense
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/32Burseraceae (Frankincense family)
    • A61K36/328Commiphora, e.g. mecca myrrh or balm of Gilead
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/35Caprifoliaceae (Honeysuckle family)
    • A61K36/355Lonicera (honeysuckle)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736Prunus, e.g. plum, cherry, peach, apricot or almond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/79Schisandraceae (Schisandra family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/046Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728Fungi, e.g. yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a composition derived from a natural product capable of inhibiting the activity of coronavirus, comprising phytoncide extracted from Chamaecyparis obtusa and a substance extracted from a natural product exhibiting antiviral activity. The composition of the present invention is derived from the natural product, thereby having no toxicity, and has high utility since the composition does not cause side effects even when applied to the human body.

Description

코로나 바이러스 활성 억제용 천연 조성물{NATURAL COMPOSITION FOR INHIBITING CORONA VIRUS ACTIVITY}Natural composition for inhibiting coronavirus activity {NATURAL COMPOSITION FOR INHIBITING CORONA VIRUS ACTIVITY}

본 발명은 코로나 바이러스의 활성을 억제할 수 있는 천연물 유래의 조성물에 관한 것으로, 편백나무로부터 추출한 피톤치드 및 항바이러스 활성을 나타내는 천연물로부터 추출한 물질을 포함한다.The present invention relates to a composition derived from a natural product capable of inhibiting the activity of coronavirus, and includes a phytoncide extracted from cypress tree and a substance extracted from a natural product exhibiting antiviral activity.

2003년 9.6% 치사율의 SARS-CoV 출현, 2015년 36%의 높은 치사율을 보인 MERS-CoV에 이어 2019년 12월부터 시작된 신종 코로나바이러스 감염증인 COVID-19는 치사율은 낮지만 돌연변이가 쉽게 일어나고, 신종 감염병을 초래할 확률과 전파력이 높아 확진자의 수가 폭증하고 있는 상황이다.Following the emergence of SARS-CoV with a mortality rate of 9.6% in 2003 and MERS-CoV with a mortality rate of 36% in 2015, COVID-19, a novel coronavirus infection that began in December 2019, has a low mortality rate, but is easily mutated. The number of confirmed patients is exploding due to the high probability of causing infectious diseases and the spreading power.

그로 인해 바이러스 감염 예방을 위하여 손 씻기, 마스크 착용 등의 '접촉방어'의 개념에서 한 단계 더 나아가 '공간방어'의 개념이 대두되면서 이와 관련한 제품들의 관심이 높아지고 있다.Accordingly, as the concept of'space defense' has emerged from the concept of'contact defense' such as washing hands and wearing a mask to prevent virus infection, interest in related products is increasing.

'공간방어'란 특정 공간의 공기 중에 떠있는 각종 세균이나 바이러스의 감염 가능성을 최소화하기 위하여, 바이러스가 존재할 가능성이 있는 공간 자체에 대하여 바이러스를 불활성화 하거나 사멸하여 바이러스의 전파 가능성을 낮추는 방법을 의미한다. 즉, 집안이나 사무실, 엘리베이터, 식당, 자동차, 호텔, 영유아 보육시설 등 일상생활 공간이나 교회, 교육장, 학교, 공연장 등의 공공장소 등에서 바이러스의 비말 및 에어로졸 타입의 코로나바이러스 감염 등을 최소화하기 위한 예방법이다.'Space defense' refers to a method of lowering the possibility of virus transmission by inactivating or killing the virus in the space itself where the virus may exist in order to minimize the possibility of infection of various bacteria or viruses floating in the air in a specific space. do. In other words, preventive measures to minimize virus droplets and aerosol-type coronavirus infections in daily living spaces such as homes, offices, elevators, restaurants, cars, hotels, and infant care facilities, or in public places such as churches, education centers, schools, and performance halls. to be.

특히, 세계보건기구 WHO에 따르면 신종플루 및 코로나 바이러스는 사람 간에 전염이 일어나고, 대부분 기침이나 재채기를 통해 공기중에 확산되는 비말로 인해 감염되는 비말 감염의 가능성이 높은 것으로 보고되고 있다. 따라서, 많은 사람이 근무하거나 생활하는 공간의 대기중에 존재하는 바이러스 입자에 대한 방역의 중요성이 날로 증가하고 있다.In particular, according to the World Health Organization WHO, H1N1 influenza and coronavirus are transmitted from person to person, and it is reported that there is a high possibility of droplet infection, which is infected by droplets that spread into the air through coughing or sneezing. Therefore, the importance of quarantine against virus particles existing in the atmosphere of a space where many people work or live is increasing day by day.

한편 편백나무(Chamaecyparis obtusa)는 노송나무라고도 하며, 겉씨식물 구과목 측백나무과의 상록교목으로서, 일본이 원산지이지만 개발을 통해 우리나라 남부 지방에서 조림수종으로 널리 재배되고 있는데, 편백나무 특유의 향으로 인해 탈취제, 항균제 등으로 사용되고 있다. On the other hand, the cypress ( Chamaecyparis obtusa ) is also known as the cypress, and is an evergreen tree of the coniferous cypress family, and although it is native to Japan, it is widely cultivated as a planted tree in southern Korea through development. It is used as a deodorant and antibacterial agent.

편백나무에서 생산되는 피톤치드(phytoncide)는 식물의 자기방어물질로써, 병원균 및 해충, 곰팡이 등에 저항하기 위해 식물이 내뿜거나 분비하는 물질로 그 자체에 살균, 살충성분이 포함되어 있다. 피톤치드의 구성물질은 테르펜을 비롯한 페놀 화합물, 알칼로이드 성분, 글리코시드 등으로 이루어진 유기화합물이며, 항균작용, 진정작용, 탈취작용, 스트레스 해소작용 등을 하는 것으로 알려져 있다. Phytoncide produced from cypress trees is a plant's self-defense material, and is a substance exhaled or secreted by plants to resist pathogens, pests, and fungi, and itself contains sterilization and insecticidal components. The constituents of phytoncide are organic compounds composed of phenolic compounds, alkaloids, glycosides, etc., including terpenes, and are known to have antibacterial, sedative, deodorant, and stress-relieving effects.

이러한 피톤치드는 화학 합성 물질이 아닌 천연 물질이고, 인간의 신체에 무리 없이 흡수되며, 항균작용, 소취작용, 진정작용 및 스트레스 해소 작용 등 수많은 기능을 하는 것으로 알려져 있다. 또한, 피톤치드는 뛰어난 살균, 항균, 세정작용으로 피부를 깨끗하게 하고 보습작용도 하며, 체내의 면역 기능을 강화하는 것으로 알려져 있다. Such phytoncide is a natural substance, not a chemical synthetic substance, and is easily absorbed by the human body, and is known to have numerous functions, such as antibacterial, deodorant, sedative, and stress relief. In addition, phytoncide is known to cleanse and moisturize the skin with excellent sterilization, antibacterial, and cleansing effects, and to strengthen immune functions in the body.

이처럼 피톤치드의 항균력, 공기정화 능력, 스트레스가 해소, 장과 심폐기능의 강화, 실내 살균작용 등의 효과를 이용한 활용 방안에 대한 여러가지 연구가 이루어지고 있으나, 이를 대기중에 분사하여 바이러스 억제 효과를 나타낼 수 있는지 등에 대해서는 아직 충분한 연구가 이루어지지 않았고, 충분한 항균 및 항바이러스 효과를 나타내기 위해 고농도의 피톤치드를 사용하는 경우 오히려 선호도가 떨어지는 문제점이 존재하였다.As such, various studies have been conducted on the use of phytoncide's antibacterial activity, air purification ability, stress relief, strengthening of intestinal and cardiopulmonary function, indoor sterilization, etc., but it can be sprayed into the atmosphere to show a virus suppression effect. Sufficient research has not yet been conducted on whether or not, and when using a high concentration of phytoncide to exhibit sufficient antibacterial and antiviral effects, there is a problem that the preference is rather low.

한국공개특허 제10-2017-0027536호Korean Patent Publication No. 10-2017-0027536

본 발명의 목적은 코로나바이러스의 활성을 억제하는 효과를 갖는 천연물 유래 추출물 및 피톤치드를 함유하는 편백수의 복합 조성물 및 이의 제조방법을 제공하는 것이다.It is an object of the present invention to provide a composite composition of cypress water containing extracts derived from natural products and phytoncide having an effect of inhibiting the activity of coronavirus, and a method for preparing the same.

본 발명의 다른 목적은 상기 조성물의 다양한 응용 형태 및 용도를 포함하여, 바이러스의 억제 또는 불활성화 방법을 제공하는 것이다.Another object of the present invention is to provide a method for inhibiting or inactivating viruses, including various application forms and uses of the composition.

상기 과제를 해결하기 위한 본 발명의 일 측면은 편백나무의 잎 및 줄기를 열수 추출하여 수득한 편백수 1200 내지 1800 중량부; 및 몰약(Commiphora myrrha Holmes), 유향나무(Boswellia Carterii), 금은화(Lonicera japonica), 백운풀(Hedyotis diffusa), 행인(杏仁), 도인(桃仁), 팔각(八角, Illicium verum Hook. f.), 봉출(蓬朮, Curcuma zedoaria), 무궁화(Hibiscus syriacus), 탱자나무(Poncirus trifoliata) 씨앗 및 말똥진흙버섯(Phellinus igniarus)으로 구성된 군에서 하나 이상 선택된 것의 혼합 추출물; 1 내지 100 중량부;를 포함하는, 항바이러스용 조성물을 제공한다.One aspect of the present invention for solving the above problem is 1200 to 1800 parts by weight of cypress water obtained by hot water extraction of leaves and stems of cypress trees; And myrrh ( Commiphora myrrha Holmes ), frankincense tree ( Boswellia Carterii ), gold silver flower ( Lonicera japonica ), baekwoon grass ( Hedyotis diffusa ), haengin (杏仁), doin (桃仁), octagon (八角, Illicium verum Hook.f. ), Bongchul (蓬朮, Curcuma zedoaria ), Mugunghwa ( Hibiscus syriacus ), Tangja tree ( Poncirus trifoliata ) seeds and horse dung mud mushroom ( Phellinus igniarus ) a mixed extract of one or more selected from the group consisting of; It provides an antiviral composition containing; 1 to 100 parts by weight.

구체적으로, 상기 편백수는 편백나무 잎 및 편백나무 줄기에 증류수를 넣고 100℃에서 2 내지 3시간 동안 열수 추출한 후 감압 농축하여 수득하고, 상기 혼합 추출물은 60 내지 70%의 에탄올을 이용하여 90℃에서 3 내지 4시간동안 열수 추출하여 수득한 것인 일 수 있다. Specifically, the cypress water is obtained by adding distilled water to cypress leaves and cypress trunks, hot water extraction at 100°C for 2 to 3 hours, and then concentration under reduced pressure, and the mixed extract is 90°C using 60 to 70% ethanol. It may be obtained by hot water extraction for 3 to 4 hours.

구체적으로, 상기 혼합 추출물은 몰약(Commiphora myrrha Holmes) 30 중량부, 유향나무(Boswellia Carterii) 20 중량부, 금은화(Lonicera japonica) 15 중량부, 백운풀(Hedyotis diffusa) 15 중량부, 행인(杏仁) 5 중량부, 도인(桃仁) 5 중량부, 팔각(八角, Illicium verum Hook. f.) 10 중량부, 봉출(蓬朮, Curcuma zedoaria) 10 중량부, 무궁화(Hibiscus syriacus) 10 중량부, 탱자나무(Poncirus trifoliata) 씨앗 5 중량부 및 말똥진흙버섯(Phellinus igniarus) 5 중량부를 혼합하고, 이를 60 내지 70%의 에탄올로 90℃에서 3 내지 4시간동안 열수 추출하여 제조한 것일 수 있으나, 이에 제한되는 것은 아니다.Specifically, the mixed extract is myrrh ( Commiphora myrrha Holmes ) 30 parts by weight, frankincense ( Boswellia Carterii ) 20 parts by weight, gold and silver ( Lonicera japonica ) 15 parts by weight, Baiyun grass ( Hedyotis diffusa ) 15 parts by weight, almond 5 Weight parts, Doin 5 parts by weight, Octagon (八角, Illicium verum Hook. f. ) 10 parts by weight, Bongchul (蓬朮, Curcuma zedoaria ) 10 parts by weight, Hibiscus syriacus 10 parts by weight, Tangja tree ( Poncirus trifoliata ) 5 parts by weight of seeds and 5 parts by weight of horse dung mud ( Phellinus igniarus ) may be mixed and prepared by hot water extraction for 3 to 4 hours at 90°C with 60 to 70% ethanol, but is limited thereto no.

본 발명에 있어서, 구체적으로 상기 천연물 유래의 추출물은 물, C1 내지 C4의 저급 알코올, 또는 이들의 혼합 용매로 추출된 것일 수 있다. 더욱 구체적으로는 증류수 또는 60 내지 70%의 에탄올을 이용해 추출된 것일 수 있으나, 이에 제한되지 않는다.In the present invention, specifically, the extract derived from the natural product may be extracted with water, a C 1 to C 4 lower alcohol, or a mixed solvent thereof. More specifically, it may be extracted using distilled water or 60 to 70% ethanol, but is not limited thereto.

구체적으로, 상기 추출물의 추출공정은 냉침, 온침, 가열, 환류 및 초음파 추출로 구성된 군에서 하나 이상 선택되는 방법을 단독 또는 혼합하여 사용할 수 있으며, 이에 제한되지 않고 필요에 따라 이를 적절히 변경하여 적용할 수 있다. Specifically, in the extraction process of the extract, one or more methods selected from the group consisting of cold needle, warm needle, heating, reflux, and ultrasonic extraction may be used alone or in combination, and are not limited thereto, and may be appropriately changed and applied as necessary. I can.

또한, 상기 추출물은 추출 또는 분획과정을 수행한 이후, 감압 여과 과정을 수행하거나 추가로 농축 및/또는 동결건조를 수행하여 농축하거나 용매를 제거할 수 있고, 구체적으로는 추출 후에 감압 농축하는 과정을 거쳐 추출물을 수득할 수 있으나, 이에 제한되지 않고 적절히 변경하여 적용 가능하다.In addition, the extract may be concentrated or the solvent may be removed by performing an extraction or fractionation process, followed by a vacuum filtration process or further concentration and/or lyophilization, and specifically, a process of concentrating under reduced pressure after extraction. The extract may be obtained through the process, but is not limited thereto and may be appropriately changed and applied.

본 발명에서 상기 “피톤치드”는 테르펜을 비롯한 페놀 화합물, 알칼로이드 성분, 글리코시드 성분으로 이루어져 인공합성이나 조합이 어려운 100% 천연물질로, 일반적으로 삼림욕을 통해 인간의 신체에 무리없이 빠르게 흡수되어, 인간에게 해로운 균들을 선택적으로 살균함으로써, 내성이 없는 강한 항균ㆍ항진균 작용, 스트레스 완화, 피부의 진정작용, 숙면 유도효과, 알레르기성 피부질환 개선 및 면역기능 증대 등의 다양한 효능을 갖는 물질이다. In the present invention, the “phytoncide” is a 100% natural substance that is difficult to artificially synthesize or combine, consisting of phenolic compounds including terpenes, alkaloids, and glycosides. In general, it is rapidly absorbed into the human body through a forest bath. By selectively sterilizing harmful bacteria, it has various effects such as strong antibacterial and antifungal action without resistance, stress relief, skin sedation, sound sleep induction effect, allergic skin disease improvement, and immune function enhancement.

이에 따라 삼림욕을 자주 할 수 없는 바쁜 현대인을 위해 방향제, 세안제, 화장품 및 의약품 등 일상생활에 접할 수 있는 여러 가지 제품에 피톤치드 성분을 첨가하여 간접적으로 삼림욕 효과를 기대하려는 제품 생산의 움직임이 활발하게 이루어지고 있다.Accordingly, for the busy modern people who cannot frequent forest bathing, the movement of product production to indirectly expect the forest bathing effect by adding phytoncide ingredients to various products that can be encountered in daily life such as fragrances, face wash, cosmetics and medicines has been actively made. Is losing.

피톤치드에 대한 연구 결과로는 식물에서 발산되는 피톤치드의 양은 물론이고 효능 또한 모두 다른 특징이 있는데, 소나무나 잣나무 등과 같은 침엽수에서 다량의 피톤치드가 발생하며, 특히, 편백나무(扁栢, Chamaecyparis obtusa)에서 가장 많은 성분 함량과 치유력이 강력한 피톤치드가 발생되는 것으로 알려져 있다.As a result of the study on phytoncide, not only the amount of phytoncide emitted from plants, but also the efficacy are all different characteristics.A large amount of phytoncide occurs in coniferous trees such as pine and Japanese pine, especially in the cypress (Chamecyparis obtusa ). It is known that phytoncide, which has the highest content and healing power, is produced.

현재 피톤치드 성분이 포함된 제품은 편백나무로부터 추출한 정유(精油, essential oil) 또는 편백수를 주로 이용하고 있으며, 여기서 정유라 함은, 식물의 꽃ㆍ꽃봉오리ㆍ잎ㆍ줄기ㆍ뿌리ㆍ천연수지(天然樹脂) 등에서 얻는 향기가 강한 휘발성 물질로 피톤치드 성분을 포함하고 있다.Currently, products containing phytoncide components mainly use essential oil or cypress water extracted from cypress trees, and the term "essential oil" refers to plant flowers, buds, leaves, stems, roots, and natural resins ( It contains phytoncide as a volatile substance with strong scent obtained from 天然樹脂).

본 발명에서 상기 “항바이러스”란 병원체 바이러스의 불활성화, 바람직하게는 영구적인 불활성화를 의미한다.In the present invention, the “antivirus” means inactivation, preferably permanent inactivation of the pathogen virus.

구체적으로, 상기 조성물에 의해 비활성화 또는 영구 비활성화가 가능한 바이러스로는 DNA 바이러스 및 RNA 바이러스일 수 있고, 구체적인 예로는 A형 인플루엔자 바이러스(사람, 새, 돼지(신형)), B형 인플루엔자 바이러스, 파라인플루엔자 바이러스, (A~E형)간염 바이러스, 홍역 바이러스, 헤르페스 바이러스, 유행성 이하선염 바이러스, 광견병 바이러스, 노로바이러스, HIV 바이러스, SARS, 조류독감, 신종플루, 에볼라 바이러스, 메르스 코로나바이러스(MERS-CoV) 및 COVID-19로 이루어진 군에서 하나 이상 선택된 것일 수 있고, 가장 구체적으로는 코로나바이러스(SARS, MERS 및 COVID-19)일 수 있으나, 이에 제한되지 않는다.Specifically, viruses that can be inactivated or permanently inactivated by the composition may be DNA viruses and RNA viruses, and specific examples are influenza A virus (human, bird, swine (new type)), influenza B virus, parainfluenza Virus, (type A~E) hepatitis virus, measles virus, herpes virus, mumps virus, rabies virus, norovirus, HIV virus, SARS, bird flu, swine flu, ebola virus, MERS coronavirus (MERS-CoV) And it may be one or more selected from the group consisting of COVID-19, and most specifically, may be a coronavirus (SARS, MERS, and COVID-19), but is not limited thereto.

본 발명의 실험예에서는 상기 사스 코로나바이러스(SARS-CoV), 메르스 코로나바이러스(MERS-CoV) 및 COVID-19(SARS-CoV-2)를 이용하여 본 발명 조성물의 항바이러스 효능을 확인하였다(표 1).In the experimental example of the present invention, the antiviral efficacy of the composition of the present invention was confirmed using the SARS coronavirus (SARS-CoV), MERS coronavirus (MERS-CoV) and COVID-19 (SARS-CoV-2) ( Table 1).

본 발명의 다른 측면은 상기 조성물을 포함하는 화장료 조성물에 관한 것이다. Another aspect of the present invention relates to a cosmetic composition comprising the composition.

본 발명의 화장료 조성물은 용액, 외용 연고, 크림, 폼, 영양 화장수, 유연 화장수, 팩, 유연수, 유액, 메이크업 베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린 크림, 선 오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면 활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취 및 스프레이로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으며, 구체적으로는 비누, 액체 세정료 또는 핸드크림일 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition of the present invention is a solution, external ointment, cream, foam, nutrient lotion, flexible lotion, pack, softening water, emulsion, makeup base, essence, soap, liquid detergent, bathing agent, sunscreen cream, sun oil, suspension, emulsion It can be prepared in a formulation selected from the group consisting of liquid, paste, gel, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch, and spray, specifically soap , It may be a liquid cleaning agent or hand cream, but is not limited thereto.

본 발명의 상기 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1 종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면 활성제, 보습제, 저급 알코올, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition of the present invention may additionally include one or more cosmetically acceptable carriers blended in general skin cosmetics, and as common ingredients, for example, oil, water, surfactants, moisturizers, lower alcohols, thickeners , A chelating agent, a colorant, a preservative, a fragrance, and the like may be appropriately blended, but are not limited thereto.

본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 화장료 조성물의 제형에 따라 다양하다.The cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the formulation of the cosmetic composition.

본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화 아연 등이 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2 종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. May be used, but is not limited thereto. These may be used alone or in combination of two or more.

본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 등이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로하드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2 종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc. may be used as a carrier component. In particular, in the case of a spray, additional chlorofluorohard It may include a propellant such as locarbon, propane/butane or dimethyl ether, but is not limited thereto. These may be used alone or in combination of two or more.

본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제 등이 이용될 수 있으며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일 등이 이용될 수 있고, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브 오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2 종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butyl glycol oil, and the like may be used, and in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan May be used, but is not limited thereto. These may be used alone or in combination of two or more.

본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타하이드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2 종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, micro Crystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used, but is not limited thereto. These may be used alone or in combination of two or more.

또한, 본 발명의 조성물은 피부에 직접 도포하거나 살포하는 등의 경피 투여 방법으로 사용될 수 있으며, 본 발명 조성물의 투여 경로는 목적조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 투여될 수 있다. In addition, the composition of the present invention may be used as a transdermal administration method such as direct application or spraying on the skin, and the administration route of the composition of the present invention may be administered through any general route as long as it can reach the target tissue.

본 발명의 조성물의 사용량은 연령, 병변의 정도 등의 개인 차이나 제형에 따라 적절하게 조절될 수 있으며, 1일 1회 내지 수회 적?韜?을 피부에 도포하여 1 주일 내지 수개월 사용될 수 있다.The amount of use of the composition of the present invention may be appropriately adjusted according to individual differences or formulations such as age and degree of lesions, and may be used from one week to several months by applying one or several times a day to the skin.

본 발명에 의해 제공되는 천연물 유래 물질 및 피톤치드를 함유하는 편백수를 포함하는 항바이러스 조성물은 여러 종류의 코로나 바이러스에 두루 우수한 항바이러스능을 보유하는 것을 확인하였고, 이를 통해 돌연변이가 잦은 코로나 바이러스에 적합한 예방제로 사용 가능할 것으로 기대되며, 우수한 제제안전성을 가진다.It was confirmed that the antiviral composition comprising cypress water containing natural substances and phytoncide provided by the present invention possesses excellent antiviral activity over various types of coronavirus, and is suitable for coronaviruses with frequent mutations through this It is expected to be used as a preventive agent and has excellent formulation safety.

상기 조성물은 피톤치드 외에도 천연물 유래의 항바이러스 효능을 갖는 다수의 추출물을 포함함으로써, 낮은 농도에서도 우수한 바이러스 억제능을 나타낼 수 있어, 고농도의 피톤치드를 사용함에 따른 불쾌감 유발 등 낮은 선호도의 문제를 해결할 수 있다.In addition to phytoncide, the composition includes a plurality of extracts having antiviral efficacy derived from natural products, so that it can exhibit excellent virus inhibitory ability even at a low concentration, thereby solving the problem of low preference, such as causing discomfort caused by using a high concentration of phytoncide.

또한, 본 발명의 조성물은 천연물로부터 유래한 것으로서 독성이 없으며, 인체에 적용하여도 부작용을 유발하지 않아 그 활용도가 높다.In addition, the composition of the present invention is derived from natural products and is not toxic, and does not cause side effects even when applied to the human body, so its utilization is high.

본 발명의 항바이러스 조성물 및 이를 이용한 스프레이는 전염의 주경로가 되는 병원, 강의실, 대중교통 등의 장소로부터 세균 또는 바이러스 등에 의한 피해(전염)를 조기에 예방할 수 있는 효과가 있다.The antiviral composition of the present invention and the spray using the same have the effect of preventing early damage (contagion) caused by bacteria or viruses from places such as hospitals, lecture rooms, and public transportation, which are the main routes of transmission.

또한 본 발명의 항바이러스 조성물 및 이를 이용한 스프레이는 병원, 강의실, 대중교통 등의 장소의 내벽, 외벽, 천장, 물품 등에 본 발명의 조성물이 잔류하여 상기 특성이 지속적으로 발현됨에도 건조가 빠르며 끈적거림이 없어 실질적으로 사용하기 수월한 효과가 있다.In addition, the antiviral composition of the present invention and the spray using the same, the composition of the present invention remains in the interior walls, exterior walls, ceilings, articles of places such as hospitals, lecture rooms, public transportation, etc. There is no practical effect that is easy to use.

본 발명의 효과는 상기한 효과로 한정되는 것은 아니며, 본 발명의 상세한 설명 또는 청구범위에 기재된 발명의 구성으로부터 추론 가능한 모든 효과를 포함하는 것으로 이해되어야 한다.The effects of the present invention are not limited to the above effects, and should be understood to include all effects that can be deduced from the configuration of the invention described in the detailed description or claims of the present invention.

이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by examples. However, the following examples are only illustrative of the present invention, and the present invention is not limited by the following examples.

실시예 1. 항바이러스 효능을 갖는 천연물 유래의 추출물 제조Example 1. Preparation of extracts derived from natural products having antiviral efficacy

본 발명의 항바이러스 조성물을 제조하기 앞서, 항바이러스 효능을 갖는 천연물 유래의 추출물을 제조하였다.Prior to preparing the antiviral composition of the present invention, an extract derived from a natural product having antiviral efficacy was prepared.

먼저, 상기 천연물 유래 추출물을 제조하기 위하여 몰약(Commiphora myrrha Holmes), 유향나무(Boswellia Carterii), 금은화(Lonicera japonica), 백운풀(Hedyotis diffusa), 행인(杏仁), 도인(桃仁), 팔각(八角, Illicium verum Hook. f.), 봉출(蓬朮, Curcuma zedoaria), 무궁화(Hibiscus syriacus), 탱자나무(Poncirus trifoliata) 씨앗 및 말똥진흙버섯(Phellinus igniarus)을 세척하고 물기를 제거하여 준비하고, 60 내지 70%의 에탄올을 이용하여 90℃에서 3 내지 4시간동안 열수 추출하였다. First, in order to prepare the extract derived from the natural product, myrrh ( Commiphora myrrha Holmes ), frankincense tree ( Boswellia Carterii ), gold silver flower ( Lonicera japonica ), baekwoon grass ( Hedyotis diffusa ), almond tree (杏仁), Doin (桃仁), octagon Illicium verum Hook.f. ), Bongchul (蓬朮, Curcuma zedoaria ), Mugunghwa ( Hibiscus syriacus ), Poncirus trifoliata seeds and horse dung mud ( Phellinus igniarus ) were washed and dried to prepare, Hot water extraction was performed at 90° C. for 3 to 4 hours using 70% ethanol.

구체적으로, 상기 천연물 유래 추출물은 몰약(Commiphora myrrha Holmes) 30 중량부, 유향나무(Boswellia Carterii) 20 중량부, 금은화(Lonicera japonica) 15 중량부, 백운풀(Hedyotis diffusa) 15 중량부, 행인(杏仁) 5 중량부, 도인(桃仁) 5 중량부, 팔각(八角, Illicium verum Hook. f.) 10 중량부, 봉출(蓬朮, Curcuma zedoaria) 10 중량부, 무궁화(Hibiscus syriacus) 10 중량부, 탱자나무(Poncirus trifoliata) 씨앗 5 중량부 및 말똥진흙버섯(Phellinus igniarus) 5 중량부를 혼합하고, 이를 60 내지 70%의 에탄올로 90℃에서 3 내지 4시간동안 열수 추출하여 제조하였다.Specifically, the extract derived from the natural product is myrrh ( Commiphora myrrha Holmes ) 30 parts by weight, frankincense tree ( Boswellia Carterii ) 20 parts by weight, gold and silver flower ( Lonicera japonica ) 15 parts by weight, Baiyun grass ( Hedyotis diffusa ) 15 parts by weight, almond (杏仁) 5 parts by weight, Doin 5 parts by weight, Octagon (八角, Illicium verum Hook.f. ) 10 parts by weight, Bongchul (蓬朮, Curcuma zedoaria ) 10 parts by weight, Hibiscus syriacus 10 parts by weight, Tangja tree ( Poncirus trifoliata ) 5 parts by weight of seeds and 5 parts by weight of horse dung mud ( Phellinus igniarus ) were mixed and prepared by hot water extraction at 90° C. for 3 to 4 hours with 60 to 70% ethanol.

실시예 2. 피톤치드를 함유하는 항바이러스 조성물의 제조Example 2. Preparation of antiviral composition containing phytoncide

피톤치드를 함유하는 항바이러스 조성물을 제조하기에 앞서, 실시예 1에서 제조한 천연물 유래 추출물과 혼합하기 위한 편백수 제조하였다.Prior to preparing the antiviral composition containing phytoncide, cypress water for mixing with the extract derived from the natural product prepared in Example 1 was prepared.

상기 편백수를 제조하기 위하여 건조된 편백나무 잎 0.5kg 및 편백나무 줄기 0.5kg을 분쇄하여 추출 용기에 담고, 상기 편백나무 잎과 줄기 1kg에 15L의 증류수를 혼합하여 100℃에서 2 내지 3시간 가열하여 열수 추출하고, 이를 400 메쉬 여과포로 여과한 다음, 감압회전농축기로 농축하였으며, 여과 후 남은 잔사에 다시 동량의 증류수를 사용하여 동일 과정으로 2번 더 추출, 여과 및 감압 농축하여 피톤치드를 함유하는 편백수를 제조하였다.To prepare the cypress water, 0.5 kg of dried cypress leaves and 0.5 kg of cypress stems are pulverized and placed in an extraction container, and 15L of distilled water is mixed with 1 kg of cypress leaves and stems and heated at 100°C for 2 to 3 hours And extracted with hot water, filtered through a 400 mesh filter cloth, and concentrated with a vacuum rotary concentrator, and extracted twice more in the same process using the same amount of distilled water to the remaining residue after filtration, filtered and concentrated under reduced pressure to contain phytoncide. Cypress water was prepared.

상기 제조방법을 통해 수득한 편백수 1500 중량부를 기준으로 상기 실시예 1의 추출물은 1 내지 100 중량부, 더욱 구체적으로는 10 내지 50 중량부, 가장 구체적으로는 30 중량부를 혼합하여 본 발명의 항바이러스 조성물을 제조하였으나, 이에 제한되는 것은 아니다.The extract of Example 1 is 1 to 100 parts by weight, more specifically 10 to 50 parts by weight, and most specifically 30 parts by weight based on 1500 parts by weight of cypress water obtained through the preparation method. Although the virus composition was prepared, it is not limited thereto.

비교예 1 내지 4의 제조Preparation of Comparative Examples 1 to 4

상기 실시예 2의 항바이러스 조성물에서 다음과 같이 조성을 달리 하면서 비교예 1 내지 4를 제조하였다.In the antiviral composition of Example 2, Comparative Examples 1 to 4 were prepared while changing the composition as follows.

비교예 1은 실시예 1의 조성물을 제조할 때 유향나무를 제외하였다는 점을 제외하고는 실시예 2와 동일한 방법을 통해 제조하였고, 비교예 2는 비교예 1에서 백운풀을 더 제외하였으며, 비교예 3은 실시예 2의 조성물에서 실시예 1을 10 중량부 포함하여 제조한 것을 제외하고는 실시예 2와 동일하게 제조하였고, 비교예 4는 실시예 2의 조성물에서 실시예 1을 100 중량부를 포함하여 제조한 것을 제외하고는 실시예 2와 동일한 방법으로 제조하였다.Comparative Example 1 was prepared through the same method as in Example 2, except that the frankincense tree was excluded when preparing the composition of Example 1, and Comparative Example 2 further excluded Baiyun grass in Comparative Example 1, and Example 3 was prepared in the same manner as Example 2, except that Example 1 was prepared including 10 parts by weight of the composition of Example 2, and Comparative Example 4 was 100 parts by weight of Example 1 in the composition of Example 2. It was prepared in the same manner as in Example 2, except that it was prepared including.

실험예 1. 세포 독성 및 바이러스 억제 효과 확인Experimental Example 1. Cytotoxicity and virus inhibition effect confirmation

상기 실시예 2 및 비교예 1 내지 4의 조성물을 대상으로 세포 독성 및 바이러스 억제 효과 확인을 위한 실험을 실시하였다.The composition of Example 2 and Comparative Examples 1 to 4 was subjected to an experiment to confirm the cytotoxicity and virus inhibitory effect.

구체적으로, 상기 실험을 위하여 국내에서 분리된 코로나 19 바이러스(BetaCoV/Korea/KCDC03/2020), 한국 환자로부터 분리 배양한 메르스 바이러스(MERS-CoV/KOR/KNIH/002_05_2015) 및 사스 코로나 바이러스(SARS-CoV)를 분양받고, 이를 배양하기 위한 세포는 vero 세포(아프리카 녹색 원숭이 신장 세포주)를 사용하였으며, 5% FBS와 페니실린/스트렙토마이신을 첨가한 DMEM(Dulbecco's modified Eagle's medium) 배지를 이용하여 유지 계대하여 준비하였다.Specifically, for the above experiment, the Corona 19 virus (BetaCoV/Korea/KCDC03/2020) isolated in Korea, the MERS virus (MERS-CoV/KOR/KNIH/002_05_2015) and SARS coronavirus (SARS) isolated and cultured from Korean patients -CoV), and cells for culturing it were vero cells (African green monkey kidney cell line), and maintenance system using DMEM (Dulbecco's modified Eagle's medium) medium supplemented with 5% FBS and penicillin/streptomycin. I prepared for it.

상기 실시예 2 및 비교예 1 내지 4의 조성물에 대한 숙주세포의 세포독성은 세포 부착성 시험(cell attachment test)으로 측정하였다. 구체적으로, 배양용 배지에 vero 세포 4.0×104cells/100 μL를 부유시켜 96 웰 플레이트의 각 웰에 접종한 후, 5% CO2, 37℃ 조건에서 24시간 배양하여 70-80% 단층(monolayer)을 형성시킨 다음, PBS로 1회 세척하고 배양액 100 μL와 상기 조성물 100uL씩을 접종하였다. 이후, 2일간 세포병변효과(Cytopathic effect, CPE)를 현미경 관찰하여 세포가 부착 증식하여 독성을 일으키지 않는지 여부를 확인하였다. The cytotoxicity of host cells to the compositions of Example 2 and Comparative Examples 1 to 4 was measured by a cell attachment test. Specifically, 4.0×10 4 cells/100 μL of vero cells were suspended in culture medium and inoculated into each well of a 96-well plate, followed by incubation for 24 hours in 5% CO 2 , 37°C conditions, and 70-80% monolayer ( monolayer) was formed, and then washed once with PBS and inoculated with 100 μL of the culture solution and 100 μL of the composition. Thereafter, the cytopathic effect (CPE) was observed under a microscope for 2 days to confirm whether the cells adhered and proliferated and did not cause toxicity.

접종용 바이러스는 75cm2의 조직배양 플라스크(Corning, USA)에서 배양하여 세포병변효과가 일어나 부착된 세포들이 떨어지면 냉동과 해동을 2번 반복한 후, 1,500×g에서 5분간 원심분리 하였다. 세포 잔해(Cell debris)는 제거하고 바이러스를 함유하고 있는 상등액을 극저온 바이알(cryogenic vial; Nalgene, USA)에 소분 후 -80℃에서 보관 사용하였다. The virus for inoculation was cultured in a 75cm 2 tissue culture flask (Corning, USA), and when the attached cells fell off due to the cell lesion effect, freezing and thawing were repeated twice, followed by centrifugation at 1,500×g for 5 minutes. Cell debris was removed, and the supernatant containing the virus was subdivided into a cryogenic vial (Nalgene, USA) and stored at -80°C.

접종용 바이러스의 감염 역가 TCID50 (50% tissue culture infective dose)를 산정하였으며, 그 결과 COVID-19 바이러스는 2.19×102/mL, MERS-CoV 바이러스는 2.35×107/mL, SARS-CoV 바이러스는 3.24×104/mL임을 확인하였다.Infectious titer TCID 50 (50% tissue culture infective dose) of the inoculation virus was calculated. As a result, COVID-19 virus was 2.19 × 10 2 /mL, MERS-CoV virus was 2.35 × 10 7 /mL, and SARS-CoV virus Was confirmed to be 3.24×10 4 /mL.

추출물에 대한 항바이러스 효능 시험은 실시예 2 및 비교예 1 내지 4의 조성물이 함유된 접종용 배양액 각 100 μL, TCID50의 10배량의 바이러스 100 μL를 접종하고, 2일간 배양 후 세포독성 시험 때와 반대로 조성물의 세포병변효과 억제 정도를 현미경 관찰하였다. 96 웰 플레이트에 샘플 당 정상세포, 바이러스만 접종한 세포, 실시예 2 및 비교예 1 내지 4의 조성물만을 첨가한 세포를 각각 2 웰씩 대조구로 설정하였다.Antiviral efficacy test for the extract was inoculated with 100 μL of each 100 μL of inoculation culture solution containing the compositions of Example 2 and Comparative Examples 1 to 4, and 100 μL of 10 times the amount of virus of TCID 50 , and cultured for 2 days and then tested for cytotoxicity. On the contrary, the degree of inhibition of the cellular lesion effect of the composition was observed under a microscope. A 96-well plate was set as a control with 2 wells each of normal cells per sample, cells inoculated with only virus, and cells to which only the compositions of Example 2 and Comparative Examples 1 to 4 were added.

세포 독성 실험 결과, 실시예 1의 조성물을 100중량부 포함하여 제조한 비교예 4를 제외하고는 실시예 2 및 비교예 1 내지 3 모두 상기 조건 하에서 세포 독성을 나타내지 않는 것을 확인하였다.As a result of the cytotoxicity test, it was confirmed that all of Example 2 and Comparative Examples 1 to 3 did not exhibit cytotoxicity under the above conditions, except for Comparative Example 4 prepared by including 100 parts by weight of the composition of Example 1.

또한, 바이러스 억제 능력 확인 실험 결과는 바이러스를 억제하지 못함(-), 부분적으로 억제함(+), 완벽히 억제함(++)으로 구별하였으며, 그 결과를 하기 표 1에 나타내었다.In addition, the test results of confirming the virus suppression ability were classified into failure to suppress the virus (-), partial suppression (+), and complete suppression (++), and the results are shown in Table 1 below.

억제능력Restraint ability 실시예 2Example 2 비교예 1Comparative Example 1 비교예 2Comparative Example 2 비교예 3Comparative Example 3 비교예 4Comparative Example 4 COVID-19COVID-19 ++++ ++ -- ++ ++++ MERS-CoVMERS-CoV ++++ ++ -- -- ++++ SARS-CoVSARS-CoV ++++ ++ -- ++ ++++

상기 표 1에 나타난 바와 같이, 본 발명의 실시예 2 조성물은 바이러스를 완벽하게 억제하는 것을 확인하였으며, 유향나무를 제외한 비교예 1은 바이러스 억제 능력이 다소 하락하였고, 유향나무 및 백운풀을 제외한 비교예 2는 다른 실험군에 비하여 현저히 효과가 하락하는 것을 확인하였다. 비교예 3은 실시예 1의 조성물을 소량 첨가함으로써 효과의 하락이 발생하여 MERS-CoV에는 항바이러스 효과를 나타내지 못하였고, 비교예 4는 우수한 바이러스 억제 효과를 나타내지만, 세포 독성 실험 결과 유일하게 세포 독성을 나타내는 것으로 확인되었으므로, 이를 인체에 적용하기에는 다소 무리가 따를 것으로 보인다.As shown in Table 1, it was confirmed that the composition of Example 2 of the present invention completely inhibited the virus, and Comparative Example 1 except for the frankincense tree slightly decreased the virus inhibitory ability, and the comparative example except for the frankincense tree and the Baiyun grass. 2 confirmed that the effect was significantly decreased compared to other experimental groups. Comparative Example 3, by adding a small amount of the composition of Example 1, caused a decrease in the effect, so that the antiviral effect was not exhibited on MERS-CoV, and Comparative Example 4 showed an excellent virus inhibitory effect, but the only cell toxicity test result As it has been confirmed to be toxic, it seems to be somewhat unreasonable to apply it to humans.

실험예 2. 분무 시 사용자의 관능감 평가 확인Experimental Example 2. User's sensory evaluation check when spraying

상기 실험예 1에서 확인한 바, 실시예 2의 조성물이 우수한 바이러스 억제능을 이용하여 일정 공간의 대기중에 존재하는 바이러스의 억제를 위해 자동분사기 또는 가습기 등에 적용하여 바이러스 감염을 예방할 수 있을 것으로 기대되므로, 상기 실시예 2 및 비교예의 조성물이 대기중에 분사될 때의 관능감 평가를 실시하였다. As confirmed in Experimental Example 1, the composition of Example 2 is expected to be able to prevent virus infection by applying an automatic sprayer or a humidifier to suppress viruses existing in the atmosphere of a certain space using excellent virus suppression ability. Sensory evaluation was performed when the compositions of Example 2 and Comparative Example were sprayed into the air.

이때, 세포 독성을 나타낼 가능성이 있는 비교예 4는 제외하였고, 비교예 1 내지 3만을 대상으로 하였다.At this time, Comparative Example 4, which may exhibit cytotoxicity, was excluded, and only Comparative Examples 1 to 3 were targeted.

상기 항바이러스 조성물에 대한 관능검사는 20 ~ 50대의 성인남녀 24명을 선정하여 실시하였으며, 구체적으로, 각 그룹별로 6명씩 나이와 성별이 골고루 분배하였고, 밀폐된 1평 공간 안에 1ml를 분사하고, 피험자가 느끼는 향 선호도, 불쾌감(강한 냄새), 어지럼증, 거북함 및 전체적인 선호도에 대해서 평가하였다. The sensory test for the antiviral composition was conducted by selecting 24 adult men and women in their 20s to 50s. Specifically, 6 people in each group were evenly distributed by age and gender, and 1ml was sprayed into a sealed 1 pyeong space, The subjects' preference for scent, discomfort (strong odor), dizziness, uncomfortableness, and overall preference were evaluated.

평점은 10점 평점법을 사용하였으며, 선호도가 높을수록 높은 점수를 주도록 하였다. 각 사람당 1회 평가가 완료되면 30분간 충분히 휴식을 취하게 하면서 완전히 환기를 시켰으며, 모두 3회 반복 평가하여 평균값을 구하였다. 그 결과는 하기 표 2에 나타내었다.A 10-point scoring method was used for the rating, and the higher the preference, the higher the score was given. When the evaluation was completed once for each person, they were completely ventilated while taking a sufficient rest for 30 minutes, and the average value was calculated by repeating evaluation three times. The results are shown in Table 2 below.

구분division 실시예 2Example 2 비교예 1Comparative Example 1 비교예 2Comparative Example 2 비교예 3Comparative Example 3 향 선호도Fragrance preference 9.19.1 8.38.3 7.77.7 8.28.2 불쾌감(강한 냄새)Discomfort (strong smell) 9.09.0 7.47.4 7.27.2 8.58.5 어지럼증Dizziness 8.98.9 8.38.3 8.18.1 8.58.5 거북함Uncomfortable 8.78.7 8.08.0 7.87.8 8.28.2 종합 선호도Overall preference 8.98.9 7.97.9 7.57.5 8.18.1

상기 표 2에 나타난 결과와 같이, 유향나무 추출물과 금은화 추출물이 전반적으로 향 선호도에 미치는 영향이 크다는 것을 확인할 수 있었으며, 그로인한 불쾌감 및 종합 선호도 모두에서 실시예 2와 비교하여 현저하게 떨어지는 결과를 보이는 것을 확인하였다. 또한, 비교예 3의 결과는 실시예 1의 조성물이 본 발명에서 제시하는 수치 범위보다 적게 포함되는 경우, 관능감 전반에 사람이 인지할 수 있을 정도로 선호도가 하락하는 것을 확인하였다.As shown in Table 2 above, it was confirmed that the frankincense tree extract and the gold silver flower extract had a large effect on the overall flavor preference, and the result was significantly inferior to that of Example 2 in both the resulting discomfort and overall preference. Confirmed. In addition, the result of Comparative Example 3 was confirmed that when the composition of Example 1 was included in less than the numerical range suggested by the present invention, the preference fell so that a person could perceive the overall sensory feeling.

실험예 3. 흡입 독성 실험 Experimental Example 3. Inhalation toxicity test

본 발명 실시예 2의 조성물이 공기중 분사되었을 때의 흡입 독성을 확인하였다.Inhalation toxicity was confirmed when the composition of Example 2 of the present invention was sprayed into the air.

구체적으로, 마우스(BALB/c) 암수 5마리씩에 대해 실시예 2의 조성물을 각각 0, 125, 250, 500 mg/m3의 농도로 매일 4시간씩 노출시켜 14일간의 사망률, 일반증상, 체중변화 및 부검 소견을 관찰하였다.Specifically, the composition of Example 2 was exposed for 4 hours daily at a concentration of 0, 125, 250 and 500 mg/m 3 for 5 males and females of mice (BALB/c) for 14 days of mortality, general symptoms, and body weight. Changes and autopsy findings were observed.

실험 기준은 식약청 고시 '의약품 등의 독성시험 기준' 및 '의약품 안전성 시험관리 기준'에 의거하여 진행하였다.Experimental standards were conducted in accordance with the'Standards for Toxicity Tests for Drugs, etc.' and'Standards for Drug Safety Test Management' announced by the KFDA.

실험 결과, 최고 농도인 500 mg/m3 에서도 사망률, 일반증상, 체중 변화, 부검 소견 등에서 이상 징후가 관찰되지 않아, 고농도(500mg/m3)로 흡입하더라도 독성을 띄지 않아 안전한 것을 확인하였다.As a result of the experiment, even at the highest concentration of 500 mg/m 3 , no abnormal signs were observed in mortality, general symptoms, weight change, autopsy findings, etc., and it was confirmed that it is safe because it is not toxic even if inhaled at a high concentration (500 mg/m 3 ).

전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 예를 들어, 단일형으로 설명되어 있는 각 구성 요소는 분산되어 실시될 수도 있으며, 마찬가지로 분산된 것으로 설명되어 있는 구성 요소들도 결합된 형태로 실시될 수 있다.The above description of the present invention is for illustrative purposes only, and those of ordinary skill in the art to which the present invention pertains will be able to understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not limiting. For example, each component described as a single type may be implemented in a distributed manner, and similarly, components described as being distributed may also be implemented in a combined form.

본 발명의 범위는 후술하는 청구범위에 의하여 나타내어지며, 청구범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.The scope of the present invention is indicated by the claims to be described later, and all changes or modified forms derived from the meaning and scope of the claims and the concept of equivalents thereof should be construed as being included in the scope of the present invention.

Claims (6)

편백나무의 잎 및 줄기에 증류수를 넣고 100℃에서 2 내지 3시간 동안 열수 추출한 후 감압 농축하여 수득한 편백수 1200 내지 1800 중량부; 및
몰약(Commiphora myrrha Holmes) 30 중량부, 유향나무(Boswellia Carterii) 20 중량부, 금은화(Lonicera japonica) 15 중량부, 백운풀(Hedyotis diffusa) 15 중량부, 행인(杏仁) 5 중량부, 도인(桃仁) 5 중량부, 팔각(八角, Illicium verum Hook. f.) 10 중량부, 봉출(蓬朮, Curcuma zedoaria) 10 중량부, 무궁화(Hibiscus syriacus) 10 중량부, 탱자나무(Poncirus trifoliata) 씨앗 5 중량부 및 말똥진흙버섯(Phellinus igniarus) 5 중량부를 혼합하고, 이를 60 내지 70%의 에탄올로 90℃에서 3 내지 4시간동안 열수 추출하여 제조한 혼합 추출물 1 내지 100 중량부;를 포함하는, 코로나바이러스 활성 억제용 조성물.
1200 to 1800 parts by weight of cypress water obtained by adding distilled water to the leaves and stems of cypress trees, hot water extraction at 100°C for 2 to 3 hours, and then concentration under reduced pressure; And
Myrrh ( Commiphora myrrha Holmes ) 30 parts by weight, Frankincense ( Boswellia Carterii ) 20 parts by weight, Gold and silver ( Lonicera japonica ) 15 parts by weight, Baekwoon grass ( Hedyotis diffusa ) 15 parts by weight, almond (杏仁) 5 parts by weight, Doin (桃仁) 5 parts by weight, octagonal (八角, Illicium verum Hook.f. ) 10 parts by weight, Bongchul (蓬朮, Curcuma zedoaria ) 10 parts by weight, Hibiscus syriacus 10 parts by weight, Poncirus trifoliata seeds 5 parts by weight And horse dung mud ( Phellinus igniarus ) 5 parts by weight of the mixture, and 1 to 100 parts by weight of a mixed extract prepared by hot water extraction for 3 to 4 hours at 90°C with 60 to 70% ethanol, and containing, coronavirus activity. Inhibitory composition.
삭제delete 삭제delete 제1항에 있어서,
상기 코로나바이러스 활성 억제용 조성물은 COVID-19, MERS-CoV 바이러스 및 SARS-CoV 바이러스로 구성된 군에서 하나 이상 선택된 것인, 항바이러스용 조성물.
The method of claim 1,
The composition for inhibiting coronavirus activity is one or more selected from the group consisting of COVID-19, MERS-CoV virus and SARS-CoV virus, antiviral composition.
제4항의 항바이러스용 조성물을 포함하는, 화장료 조성물.A cosmetic composition comprising the composition for antiviral of claim 4. 제4항의 항바이러스용 조성물을 포함하는, 스프레이용 항바이러스 수분산 조성물.An antiviral aqueous dispersion composition for spray comprising the composition for antiviral of claim 4.
KR1020200090797A 2020-07-22 2020-07-22 Natural composition for inhibiting corona virus activity KR102213514B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020200090797A KR102213514B1 (en) 2020-07-22 2020-07-22 Natural composition for inhibiting corona virus activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200090797A KR102213514B1 (en) 2020-07-22 2020-07-22 Natural composition for inhibiting corona virus activity

Publications (1)

Publication Number Publication Date
KR102213514B1 true KR102213514B1 (en) 2021-02-08

Family

ID=74560103

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200090797A KR102213514B1 (en) 2020-07-22 2020-07-22 Natural composition for inhibiting corona virus activity

Country Status (1)

Country Link
KR (1) KR102213514B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102397365B1 (en) * 2022-02-17 2022-05-13 동양특수목재 주식회사 Antiviral composition comprising chlorine dioxide solution and natural product-derived substance
WO2023001919A1 (en) * 2021-07-20 2023-01-26 Christoph Von Keudell Use of boswellia for treating sars-cov-2 infection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005068089A (en) * 2003-08-26 2005-03-17 Hinoki Shinyaku Kk Coronavirus disinfectant
KR20170027536A (en) 2015-09-02 2017-03-10 최승호 production technology for concentration-adjustable high quality phytoncide extract
KR20170129575A (en) * 2016-05-17 2017-11-27 주식회사 한국목조문화연구원 Zika virus killer, mosquito repellent and method for mosquito repellent
KR102138654B1 (en) * 2020-05-29 2020-07-28 김성재 Antiviral composition comprising natural substance-derived substance and phytoncide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005068089A (en) * 2003-08-26 2005-03-17 Hinoki Shinyaku Kk Coronavirus disinfectant
KR20170027536A (en) 2015-09-02 2017-03-10 최승호 production technology for concentration-adjustable high quality phytoncide extract
KR20170129575A (en) * 2016-05-17 2017-11-27 주식회사 한국목조문화연구원 Zika virus killer, mosquito repellent and method for mosquito repellent
KR102138654B1 (en) * 2020-05-29 2020-07-28 김성재 Antiviral composition comprising natural substance-derived substance and phytoncide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of medicinal chemistry, 2007, 50(17), pp. 4087-4095* *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023001919A1 (en) * 2021-07-20 2023-01-26 Christoph Von Keudell Use of boswellia for treating sars-cov-2 infection
KR102397365B1 (en) * 2022-02-17 2022-05-13 동양특수목재 주식회사 Antiviral composition comprising chlorine dioxide solution and natural product-derived substance

Similar Documents

Publication Publication Date Title
KR102138654B1 (en) Antiviral composition comprising natural substance-derived substance and phytoncide
CN104212272B (en) Antibacterial and environment-friendly lavender interior wall latex paint
CN103462834A (en) Room-temperature volatile natural plant essential oil mosquito repelling gel
KR102124592B1 (en) Hand-disinfectant composition for antibacterial and antivirus containing the extracts of natural material
KR20180069278A (en) Insect repellent composition and preparing method thereof
KR102213514B1 (en) Natural composition for inhibiting corona virus activity
CN102258063A (en) Chinese medicinal air freshening bactericide
CN104094977A (en) Composition with insect-expelling sterilization disinfection effects and application thereof
KR101765832B1 (en) Essential Oils with antibacterial substance
KR102292707B1 (en) Antiviral composition comprising natural substance-derived substance and acidic hypochlorous acid
CN109745514A (en) A kind of composition and its preparation method and application with anti-bacteria and anti-virus
CN109105398A (en) A kind of plant source extraction bactericidal deodorant and preparation method thereof for environmental improvement
CN102428972A (en) Liquidd mosquito-repellent incense made of folium artemisiae argyi and preparation method thereof
KR20170021573A (en) External use sanitizers containing hinoki cypress leaf extract and lemon leaf extract and manufacturing method of the same
KR20160076816A (en) Natural Preservative Composition
KR20110000216A (en) Composition for aromatic containing extracts of pine needlesand, artemisia, green tea leaves and the manufacturing method thereof
KR20150029881A (en) Mosquito repellent compositions
KR102156982B1 (en) Cosmetic composition with deodorization and antimicrobial effect containing complex extract of peppermint, oregano, ginger and cinnamon
KR20160079459A (en) Cleaning or disinfecting composition having antiviral activity by containing green tea extract as active component
CN104758322A (en) Composition capable of expelling insects, killing bacteria, sterilizing, and relieving nerve, and applications thereof
KR101898060B1 (en) Natural aroma essential oil water soluble composition for humidifier disinfectant and the method of manufaturing the same
CN105708763A (en) Artemisia argyi Levl extract-containing floral water and preparation method thereof
KR20150006243A (en) Perfume Composition Containing Chamaecyparis Obtusa Phytoncide
KR102421688B1 (en) Antibacterial functional cosmetic composition for anti-oxidation, anti-inflammatory and anti-aging having gardenia floride flower extract, pelargonium graveolens extract and salvia officinalis extract
KR101629031B1 (en) Fragrance composition comprising fermented rose extract by Basidomycetes and manufacturing method thereof

Legal Events

Date Code Title Description
GRNT Written decision to grant